Chemomab Therapeutics (CMMB) Income from Continuing Operations (2017 - 2025)
Chemomab Therapeutics posted quarterly Income from Continuing Operations of 16117000.0 for Q4 2025, up 35.34% year-on-year from 11908244.92 in Q4 2024, and down 1025.2% on a QoQ basis from 1742000.0 in Q3 2025.
Chemomab Therapeutics (CMMB) has 8 years of Income from Continuing Operations data on file, last reported at 16117000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations rose 35.34% year-over-year to 16117000.0; the trailing twelve-month figure through Dec 2025 stood at 35819000.0 (down 156.86% YoY), and the FY2025 full-year result was 8995000.0, up 35.5% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 16117000.0, down from 1742000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 8711000.0 in Q1 2023 and bottomed at 24927000.0 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 3483000.0 (2024), against an average of 213705.88.
- The widest annual swing landed in 2022, when Income from Continuing Operations soared 372.24%; it then sank 829.5% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 5036000.0 in 2021, then soared by 263.86% to 8252000.0 in 2022, then tumbled by 58.59% to 3417000.0 in 2023, then tumbled by 829.5% to 24927000.0 in 2024, then jumped by 35.34% to 16117000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 16117000.0 (Q4 2025), 1742000.0 (Q3 2025), and 24927000.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | -16.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16.12 Mn |
| Sep 30, 2025 | 1.74 Mn |
| Dec 31, 2024 | -24.93 Mn |
| Sep 30, 2024 | 3.48 Mn |
| Jun 30, 2024 | 3.63 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Dec 31, 2023 | 3.42 Mn |
| Sep 30, 2023 | 4.19 Mn |
| Jun 30, 2023 | 7.90 Mn |
| Mar 31, 2023 | 8.71 Mn |
| Dec 31, 2022 | 8.25 Mn |
| Sep 30, 2022 | 8.08 Mn |
| Jun 30, 2022 | 7.28 Mn |
| Mar 31, 2022 | -5.10 Mn |
| Dec 31, 2021 | -5.04 Mn |
| Sep 30, 2021 | -2.97 Mn |
| Jun 30, 2021 | -2.77 Mn |
| Dec 31, 2019 | -9.21 Mn |
| Sep 30, 2019 | 16.78 Mn |
| Jun 30, 2019 | 1.67 Mn |
| Mar 31, 2019 | 18.31 Mn |
| Dec 31, 2018 | 1.80 Mn |
| Sep 30, 2018 | 2.50 Mn |
| Jun 30, 2018 | 4.97 Mn |
| Mar 31, 2018 | 3.48 Mn |
| Dec 31, 2017 | 1.84 Mn |